About NuVision

NuVision® is a spin-out company from the University of Nottingham, incorporated July 2014. The company was established to commercialise high quality and affordable biotherapies for treating ‘front of the eye’ disease and trauma. The founder of NuVision®, Dr Andrew Hopkinson is the Principal Research Fellow in Academic Ophthalmology within the Division of Clinical Neuroscience at the University of Nottingham. The business is co-owned by the founders, Dr Andrew Hopkinson (CEO), Professor Harminder Dua (Clinical Director), the directors Mr Bryan Lister (COO), Dr Helen Shaw (Medical director) and the University of Nottingham.

Mission

Improving patient care and quality of life through the delivery of high quality, effective and affordable cutting-edge wound care therapies.

Vision

To become a global leader in development, delivery and commercialisation of disruptive regenerative therapies.

What makes us unique

NuVision spun out of a strong academic translational research setting, with 20 years of multidisciplinary research expertise. The need for NuVision was identified when a significant body of evidence was established around deficiencies in the way amniotic membrane was currently produced for clinical use. The University group developed solid evidence based underpinning research that challenging clinical limitations in regenerative therapies to be overcome. NuVision was born as a vehicle to translate the innovations into superior and effective solutions to improve patient care.

Our Journey

Learn more about our journey…

” … be a global leader in regenerative medicine”.

{

A message from our Founder and Visionary

With a strong, experienced team, supported by a history of innovative research, we have the products that have the potential to revolutionise wound care worldwide.  Having over 15 year’s expertise in ocular regenerative medicine, and personally evolving Omnigen from concept to commercialisation, I believe NuVision has endless potential for growth.

Andrew Hopkinson
Founder and CEO, NuVision Biotherapies

How we’re Funded

Mercia Fund Management (MFM), a national fund management business has committed £379,000 in seed funding to NuVision Biotherapies Ltd, to develop effective and affordable eye care medical solutions for humans and animals. In addition, we have secured funding of £70,000 from the University of Nottingham’s Innovation Board to establish Omnigen™ manufacturing. This has been supported by £75k of Nottingham Council Technology Fund (N’Tech) and most recently dual Innovate UK funding in the form of a £25k Smart Proof of Market & £150k Biomedical Catalyst feasibility study award.

The team

NuVision is managed by an expert team of directors encompassing essential skills of business development, clinical ophthalmic surgery, medical affairs, GMP manufacturing and research and development. Together we create a unique dynamic that will enable the company to grow and evolve to redefine sight saving biotherapies.

Want to learn more about us?

8 + 11 =